Your English writing platform
Discover LudwigExact(20)
Urothelial carcinoma makes up the majority of bladder cancers and has a high likelihood of returning after treatment.
The majority of bladder tumors are non-muscle invasive at diagnosis, and there is a high rate of tumor recurrence and progression even after local surgical therapy.
The majority of bladder cancers (90%) are "transitional cell carcinomas" (TCC) [ 2].
In the majority of bladder ruptures, there is a history of significant abdominal trauma.
In conclusion, G1 restriction point defects can be identified in the majority of bladder carcinomas.
The majority of bladder cancers are superficial, non-muscle-invasive tumours with a good prognosis.
Similar(39)
The very low prevalence of nonurothelial cancer of the urinary bladder [ 3] suggests that the vast majority of the bladder malignancies assessed in the latter studies were of urothelial cell origin.
Although the majority of human bladder cancer is superficial at the time of detection, the recurrence rate and the risk of progression to advanced disease are high (Hall et al. 2007; Kaufman et al. 2009; Faba et al. 2012; Nargund et al. 2012).
The hitherto best known molecular event predictive of advanced malignant development is the loss of p53 function, which is found in the majority of progressed bladder cancers and, notably, in CIS [ 4, 5].
Together, these data reveal a recurring theme that structural damage affecting both PTEN alleles is infrequent in the majority of human bladder cancers, raising the interesting possibility that functional inactivation of PTEN contributes significantly to PTEN deficiency.
Although the majority of urinary bladder urothelial carcinoma (UBUC) is papillary and non- or superficially invasive, cured most of the time by curettage, some UBUCs develop relentless local recurrence followed by lethal distal spreading [ 18, 19].
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com